Unfractionated Heparin Market: Snapshot
The global unfractionated heparin market is set to collect handsome revenues during the forecast period of 2019 to 2027. This growth is attributed to a plethora of factors. Unfractionated heparin is a naturally occurring anticoagulant. Owing to its ability to prevent blood clots, unfractionated heparin is widely used in heart lungs, and dialysis machines. At the same time, it is effective for treating blood clotting disorders such as pulmonary embolism and deep venous thrombosis. All these applications suggest that the global unfractionated heparin market will witness stupendous demand avenues in the forthcoming years.
Unfractionated heparin is gaining traction owing to the plethora of features it holds. It is widely accepted due to its instantaneous onset of action, uncomplicated laboratory monitoring, short half-life, and ability to get reversed (protamine). Apart from this, it is cost-efficient. Unfractionated heparin is also used for treating venous thromboembolism (VTE) including pulmonary embolism (PE) and deep vein thrombosis (DVT). This factor is stimulating the growth of the global unfractionated heparin industry.
In recent years, there is a considerable increase in the number of surgical procedures. This factor is working as a driver for the global unfractionated heparin market. Vendors working in the market for unfractionated heparin hold phenomenal avenues for growth during forthcoming years. One of the key reasons for this growth is the patent expiration for major unfractionated heparin.
On the regional front, the unfractionated heparin market is expected to gain lucrative avenues in Europe. A key reason for this growth is considerable growth in the number of research activities and increased cases of diseases in the region. In addition to this, the market for unfractionated heparin is expected to grow at a swift speed in Asia Pacific. Key factors supporting the growth of the unfractionated heparin market are an increase in the older population, an improved initiative by government bodies to advance the healthcare sector, and the presence of major players in the region.
Global: Regional Outlook
Companies Covered in Global Unfractionated heparin market Report
Global Unfractionated Heparin Market - Segmentation
Source |
Bovine Porcine |
Distribution Channel |
Hospital Pharmacies Retail Pharmacies Online Pharmacies |
Region |
North America Europe Asia Pacific Latin America Middle East & Africa |
Unfractionated heparin market to reach US$ 1.7 Bn by 2027
The global market is to expand at a CAGR of 6.4% from 2019 to 2027
The global market is driven by an increasing number of surgical procedures
Asia Pacific is expected to account for highest market share during the forecast period
Key players in the global unfractionated heparin industry include Becton, Dickinson and Company, bioMérieux S.A., Bio-Rad Laboratories, Inc, Eiken Chemical Co, Ltd.
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology
2.3. Acronyms Used
3. Executive Summary
4. Market Overview
4.1. Product Overview
4.2. Drivers and Restraints Snapshot Analysis
4.3. Drivers
4.3.1. Rise in the incidence of coagulation and renal and heart diseases
4.3.2. Inclination of slaughterhouse owners toward entering into the crude unfractionated heparin processing business
4.3.3. Ban on imports from China to boost production in Europe
4.4. Restraints
4.4.1. Availability of alternative anticoagulants
4.4.2. Enhanced quality control measures
4.4.3. Patent expiry and increasing use of off-label products
4.5. Opportunities
4.5.1. Biosimilar-based heparin products
4.5.2. Heparin diversification: alternative sources of unfractionated heparin
4.6. Key Trends
4.7. Opportunity Analysis
4.8. Global Unfractionated Heparin Market Size (US$ Mn) Forecast
5. Global Unfractionated Heparin Market Analysis, by Source
5.1. Key Findings
5.2. Introduction
5.3. Global Unfractionated Heparin Market Value Share Analysis, by Source
5.4. Global Unfractionated Heparin Market Forecast, by Source
5.4.1. Bovine
5.4.2. Porcine
5.5. Global Unfractionated Heparin Market Analysis, by Source
5.6. Global Unfractionated Heparin Market Attractiveness Analysis, by Source
6. Global Unfractionated Heparin Market Analysis, by Distribution Channel
6.1. Key Findings
6.2. Introduction
6.3. Global Unfractionated Heparin Market Value Share Analysis, by Distribution Channel
6.4. Global Unfractionated Heparin Market Forecast, by Distribution Channel
6.4.1. Hospital Pharmacies
6.4.2. Retail Pharmacies
6.4.3. Online Pharmacies
6.5. Global Unfractionated Heparin Market Analysis, by Distribution Channel
6.6. Global Unfractionated Heparin Market Attractiveness Analysis, by Distribution Channel
7. Global Unfractionated Heparin Market Analysis, by Region
7.1. Global Unfractionated Heparin Market Scenario, by Country
7.2. Global Unfractionated Heparin Market Value Share Analysis, by Region
7.3. Global Unfractionated Heparin Market Forecast, by Region
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. Middle East and Africa
7.4. Global Unfractionated Heparin Market Attractiveness Analysis, by Region
8. North America Unfractionated Heparin Market Analysis
8.1. Key Findings
8.2. North America Unfractionated Heparin Market Overview
8.3. North America Unfractionated Heparin Market Value Share Analysis, by Source
8.4. North America Unfractionated Heparin Market Forecast, by Source
8.5. North America Unfractionated Heparin Market Value Share Analysis, by Distribution Channel
8.6. North America Unfractionated Heparin Market Forecast, by Distribution Channel
8.7. North America Unfractionated Heparin Market Attractiveness Analysis
8.8. North America Unfractionated Heparin Market Value Share Analysis, by Country
8.8.1. U.S.
8.8.2. Canada
9. Europe Unfractionated Heparin Market Analysis
9.1. Key Findings
9.2. Europe Unfractionated Heparin Market Overview
9.3. Europe Unfractionated Heparin Market Value Share Analysis, by Source
9.4. Europe Unfractionated Heparin Market Forecast, by Source
9.5. Europe Unfractionated Heparin Market Value Share Analysis, by Distribution Channel
9.6. Europe Unfractionated Heparin Market Forecast, by Distribution Channel
9.7. Europe Unfractionated Heparin Market Attractiveness Analysis
9.8. Europe Unfractionated Heparin Market Value Share Analysis, by Country
9.9. Europe Unfractionated Heparin Market Forecast, by Country
9.9.1. Germany
9.9.2. U.K.
9.9.3. France
9.9.4. Italy
9.9.5. Spain
9.9.6. Rest of the Europe
10. Asia Pacific Unfractionated Heparin Market Analysis
10.1. Key Findings
10.2. Asia Pacific Unfractionated Heparin Market Overview
10.3. Asia Pacific Unfractionated Heparin Market Value Share Analysis, by Source
10.4. Asia Pacific Unfractionated Heparin Market Forecast, by Source
10.5. Asia Pacific Unfractionated Heparin Market Value Share Analysis, by Distribution Channel
10.6. Asia Pacific Unfractionated Heparin Market Forecast, by Distribution Channel
10.7. Asia Pacific Unfractionated Heparin Market Attractiveness Analysis
10.8. Asia Pacific Unfractionated Heparin Market Value Share Analysis, by Country
10.9. Asia Pacific Unfractionated Heparin Market Forecast, by Country
10.9.1. China
10.9.2. India
10.9.3. Japan
10.9.4. Australia
10.9.5. Indonesia
10.9.6. Malaysia
10.9.7. Rest of Asia Pacific
11. Latin America Unfractionated Heparin Market Analysis
11.1. Key Findings
11.2. Latin America Unfractionated Heparin Market Overview
11.3. Latin America Unfractionated Heparin Market Value Share Analysis, by Source
11.4. Latin America Unfractionated Heparin Market Forecast, by Source
11.5. Latin America Unfractionated Heparin Market Value Share Analysis, by Distribution Channel
11.6. Latin America Unfractionated Heparin Market Forecast, by Distribution Channel
11.7. Latin America Unfractionated Heparin Market Attractiveness Analysis
11.8. Latin America Unfractionated Heparin Market Value Share Analysis, by Country
11.9. Latin America Unfractionated Heparin Market Forecast, by Country
11.9.1. Brazil
11.9.2. Mexico
11.9.3. Rest of LATAM
12. Middle East & Africa Unfractionated Heparin Market Analysis
12.1. Key Findings
12.2. Middle East & Africa Unfractionated Heparin Market Overview
12.3. Middle East & Africa Unfractionated Heparin Market Value Share Analysis, by Source
12.4. Middle East & Africa Unfractionated Heparin Market Forecast, by Source
12.5. Middle East & Africa Unfractionated Heparin Market Value Share Analysis, by Distribution Channel
12.6. Middle East & Africa Unfractionated Heparin Market Forecast, by Distribution Channel
12.7. Middle East & Africa Unfractionated Heparin Market Attractiveness Analysis
12.8. Middle East & Africa Unfractionated Heparin Market Value Share Analysis, by Country
12.9. Middle East & Africa Unfractionated Heparin Market Forecast, by Country
12.9.1. GCC Countries
12.9.2. South Africa
12.9.3. Israel
12.9.4. Rest of Middle East & Africa
13. Competition Landscape
13.1. Market Share Analysis
13.2. Competition Matrix
13.2.1. Fresenius SE & Co. KGaA
13.2.1.1. Company Details
13.2.1.2. Business Overview
13.2.1.3. Financial Overview
13.2.1.4. Strategic Overview
13.2.1.5. SWOT Analysis
13.2.2. Pfizer, Inc.
13.2.2.1. Company Details
13.2.2.2. Business Overview
13.2.2.3. Financial Overview
13.2.2.4. Strategic Overview
13.2.2.5. SWOT Analysis
13.2.3. LEO Pharma A/S
13.2.3.1. Company Details
13.2.3.2. Business Overview
13.2.3.3. Financial Overview
13.2.3.4. Strategic Overview
13.2.3.5. SWOT Analysis
13.2.4. Baxter International Inc.
13.2.4.1. Company Details
13.2.4.2. Business Overview
13.2.4.3. Financial Overview
13.2.4.4. Strategic Overview
13.2.4.5. SWOT Analysis
13.2.5. B. Braun Melsungen AG
13.2.5.1. Company Details
13.2.5.2. Business Overview
13.2.5.3. Financial Overview
13.2.5.4. Strategic Overview
13.2.5.5. SWOT Analysis
13.2.6. Sagent Pharmaceuticals, Inc. (Nichi-Iko Pharmaceutical Co.)
13.2.6.1. Company Details
13.2.6.2. Business Overview
13.2.6.3. Financial Overview
13.2.6.4. Strategic Overview
13.2.6.5. SWOT Analysis
13.2.7. Mylan Inc.
13.2.7.1. Company Details
13.2.7.2. Business Overview
13.2.7.3. Financial Overview
13.2.7.4. Strategic Overview
13.2.7.5. SWOT Analysis
13.2.8. Other Prominent Players
List of Tables
Table 1: Global Unfractionated Heparin Market Value (US$ Mn) Forecast, by Source, 2017–2027
Table 2: Global Unfractionated Heparin Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 3: Global Unfractionated Heparin Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 4: North America Unfractionated Heparin Market Value (US$ Mn) Forecast, by Source, 2017–2027
Table 5: North America Unfractionated Heparin Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 6: North America Unfractionated Heparin Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 7: Europe Unfractionated Heparin Market Value (US$ Mn) Forecast, by Source, 2017–2027
Table 8: Europe Unfractionated Heparin Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 9: Europe Unfractionated Heparin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 10: Asia Pacific Unfractionated Heparin Market Value (US$ Mn) Forecast, by Source, 2017–2027
Table 11: Asia Pacific Unfractionated Heparin Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 12: Asia Pacific Unfractionated Heparin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 13: Latin America Unfractionated Heparin Market Value (US$ Mn) Forecast, by Source, 2017–2027
Table 14: Latin America Unfractionated Heparin Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 15: Latin America Unfractionated Heparin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 16: Middle East & Africa Unfractionated Heparin Market Value (US$ Mn) Forecast, by Source, 2017–2027
Table 17: Middle East & Africa Unfractionated Heparin Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 18: Middle East & Africa Unfractionated Heparin Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 19: Fresenius SE & Co. KGaA Products Offering
Table 20: Pfizer, Inc. products offering
Table 21: Leo Pharma A/S products offering
Table 22: Baxter International Inc. Products Offering
Table 23: B.Braun Melsungen AG Products Offering
Table 24: Sagent Pharmaceuticals, Inc. Products Offering
Table 25: Mylan Inc. Products Offering
List of Figures
Figure 01: Global Unfractionated Heparin Market Share (US$ Mn), by Distribution Channel, 2016
Figure 02: Global Unfractionated Heparin Market Share (%), by Source, 2016
Figure 03: Revenue Share, 2018
Figure 04: Global Unfractionated Heparin Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), 2019–2027
Figure 05: Market Value Share, by Source (2018)
Figure 06: Market Value Share, by Distribution Channel (2018)
Figure 07: Market Value Share, by Region (2018)
Figure 08: Global Unfractionated Heparin Market Value Share Analysis, by Source, 2018 and 2027
Figure 09: Global Unfractionated Heparin Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Bovine, 2017–2027
Figure 10: Global Unfractionated Heparin Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Porcine, 2017–2027
Figure 11: Global Unfractionated Heparin Market Attractiveness, by Source
Figure 12: Global Unfractionated Heparin Market Value Share, by Distribution Channel, 2018 and 2027
Figure 13: Global Unfractionated Heparin Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027
Figure 14: Global Unfractionated Heparin Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027
Figure 15: Global Unfractionated Heparin Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027
Figure 16: Global Unfractionated Heparin Market Attractiveness, by Distribution Channel
Figure 17: Global Unfractionated Heparin Market Value Share, by Region, 2018 and 2027
Figure 18: Global Unfractionated Heparin Market Attractiveness, by Region
Figure 19: North America Unfractionated Heparin Market Size (US$ Mn) Forecast, 2019–2027
Figure 20: North America Unfractionated Heparin Market Attractiveness Analysis, by Country, 2019–2027
Figure 21: North America Unfractionated Heparin Market Value Share Analysis, by Source, 2018 and 2027
Figure 22: North America Unfractionated Heparin Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 23: North America Unfractionated Heparin Market Attractiveness Analysis, by Source, 2019–2027
Figure 24: North America Unfractionated Heparin Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 25: North America Unfractionated Heparin Market Value Share Analysis, by Country, 2018 and 2027
Figure 26: Europe Unfractionated Heparin Market Size (US$ Mn) Forecast, 2019–2027
Figure 27: Europe Unfractionated Heparin Market Attractiveness Analysis, by Country/Sub-region
Figure 28: Europe Unfractionated Heparin Market Value Share Analysis, by Source, 2018 and 2027
Figure 29: Europe Unfractionated Heparin Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 30: Europe Unfractionated Heparin Market Attractiveness Analysis, by Source
Figure 31: Europe Unfractionated Heparin Market Attractiveness Analysis, by Distribution Channel
Figure 32: Europe Unfractionated Heparin Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 33: Asia Pacific Unfractionated Heparin Market Size (US$ Mn) Forecast, 2019–2027
Figure 34: Asia Pacific Unfractionated Heparin Market Attractiveness Analysis, by Country/Sub-region
Figure 35: Asia Pacific Unfractionated Heparin Market Value Share Analysis, by Source, 2018 and 2027
Figure 36: Asia Pacific Unfractionated Heparin Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 37: Asia Pacific Unfractionated Heparin Market Attractiveness Analysis, by Source
Figure 38: Asia Pacific Unfractionated Heparin Market Attractiveness Analysis, by Distribution Channel
Figure 39: Asia Pacific Unfractionated Heparin Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 40: Latin America Unfractionated Heparin Market Size (US$ Mn) Forecast, 2019–2027
Figure 41: Latin America Unfractionated Heparin Market Attractiveness Analysis, by Country/Sub-region
Figure 42: Latin America Unfractionated Heparin Market Value Share Analysis, by Source, 2018 and 2027
Figure 43: Latin America Unfractionated Heparin Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 44: Latin America Unfractionated Heparin Market Attractiveness Analysis, by Source
Figure 45: Latin America Unfractionated Heparin Market Attractiveness Analysis, by Distribution Channel
Figure 46: Latin America Unfractionated Heparin Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 47: Middle East & Africa Unfractionated Heparin Market Size (US$ Mn) Forecast, 2019–2027
Figure 48: Middle East & Africa Unfractionated Heparin Market Attractiveness Analysis, by Country
Figure 49: Middle East & Africa Unfractionated Heparin Market Value Share Analysis, by Source, 2018 and 2027
Figure 50: Middle East & Africa Unfractionated Heparin Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 51: Middle East & Africa Unfractionated Heparin Market Attractiveness Analysis, by Source
Figure 52: Middle East & Africa Unfractionated Heparin Market Attractiveness Analysis, by Distribution Channel
Figure 53: Middle East & Africa Unfractionated Heparin Market Value Share Analysis, by Country, 2018 and 2027
Figure 54: Fresenius SE & Co. KGaA Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 55: Fresenius SE & Co. KGaA R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2015–2016
Figure 56: Fresenius SE & Co. KGaA Breakdown of Net Sales, By Region 2016
Figure 57: Fresenius SE & Co. KGaA Breakdown of Net Sales, by Segment, (overall company level), 2016
Figure 58: Pfizer, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 59: Pfizer, Inc. R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2015–2016
Figure 60: Pfizer, Inc. Breakdown of Net Sales, By Region 2016
Figure 61: Pfizer, Inc. Breakdown of Net Sales, By Business Segments, 2017
Figure 62: LEO Pharma A/S Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 63: LEO Pharma A/S Breakdown of Net Sales, By Region, 2017
Figure 64: LEO Pharma A/S Breakdown of Net Sales, By Business Segments, 2017
Figure 65: Baxter International Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 66: Baxter International Inc. R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2015–2016
Figure 67: Baxter International Inc. Breakdown of Net Sales, By Region 2016
Figure 68: Baxter International Inc. Breakdown of Net Sales, (Overall Company Level), 2016
Figure 69: B. Braun Melsungen AG Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 70: B. Braun Melsungen AG R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2015–2016
Figure 71: B. Braun Melsungen AG Breakdown of Net Sales, By Region 2016
Figure 72: B. Braun Melsungen AG Breakdown of Net Sales, (Overall Company Level), 2016
Figure 73: Mylan Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 74: Mylan Inc. R&D Intensity and Sales & Marketing Intensity (%) 2014–2016
Figure 75: Mylan Inc. Breakdown of Net Sales, By Region, 2016